{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:06:04Z","timestamp":1791630364619,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NCT04520165"],"award-info":[{"award-number":["NCT04520165"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.chest.2023.01.037","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T02:29:51Z","timestamp":1675391391000},"page":"1368-1379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9558-5878","authenticated-orcid":false,"given":"Catherine","family":"Moermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Brion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gerday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Nekoee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Poulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Bricmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Henket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Guissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2023.01.037_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2023.01.037_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.chest.2023.01.037_bib3","first-page":"669","article-title":"Real-world effectiveness of benralizumab on asthma exacerbations: results from the ZEPHYR 1 study","volume":"128","author":"Carstens","year":"2021"},{"issue":"6","key":"10.1016\/j.chest.2023.01.037_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-word experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.chest.2023.01.037_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00117-2020","article-title":"Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena","volume":"56","author":"Mukherjee","year":"2020","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2023.01.037_bib6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to Anti\u2013IL-5 biologics in severe asthma\u2014a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.chest.2023.01.037_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2023.01.037_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2023.01.037_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Howarth","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.chest.2023.01.037_bib10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaip.2020.10.035","article-title":"The Relationship of asthma biologics to remission for asthma","volume":"9","author":"Menzies-Gow","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.chest.2023.01.037_bib11","doi-asserted-by":"crossref","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission\u2014what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2023.01.037_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.chest.2023.01.037_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2023.01.037_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2023.01.037_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2023.01.037_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/thorax.2003.011130","article-title":"Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma","volume":"59","author":"Delvaux","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.chest.2023.01.037_bib17","article-title":"Methodology for sputum induction and laboratory processing","volume":"130","author":"Guiot","year":"2017","journal-title":"J\u00a0Vis Exp"},{"issue":"6","key":"10.1016\/j.chest.2023.01.037_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.202104-1040LE","article-title":"Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma","volume":"204","author":"Couillard","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2023.01.037_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2023.01.037_bib20","first-page":"70","article-title":"Heterogeneous response of airway eosinophilia to anti-IL-5 biologics in severe asthma patients","volume":"12","author":"\u0160oki\u0107","year":"2022","journal-title":"J\u00a0Pers Med"},{"issue":"2","key":"10.1016\/j.chest.2023.01.037_bib21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1164\/rccm.201009-1434OC","article-title":"Presence in sputum of functional dust mite-specific IgE antibodies in intrinsic asthma","volume":"184","author":"Mouthuy","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2023.01.037_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058388","article-title":"Sputum IgE and cytokines in asthma: relationship with sputum cellular profile","volume":"8","author":"Manise","year":"2013","journal-title":"PLoS One"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223001691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223001691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T17:43:11Z","timestamp":1727286191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223001691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0012369223001691"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.01.037","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}